((自动化翻译由路透提供，请见免责声明 ))
10月11日 - ** 杰富瑞（Jefferies）对药物开发商Nurix Therapeutics 的评级为 "买入"，目标价为41美元，这是华尔街的最高价。
** 杰富瑞的 "买入 "评级是该股自7月以来的首个看涨评级--LSEG
** 券商的PT较该股上次收盘价上涨约88%。
** 该公司用于治疗癌症和炎症疾病的蛋白质调节药物的早期数据前景看好，在2025年具有 "举足轻重的潜力"--杰富瑞
** 券商预计该药物调整后的峰值销售额约为 28 亿美元
** 跟踪 NRIX 的 13 位分析师的平均评级为 "买入"；中位数 PT 为 30 美元
** 截至上次收盘，股价已上涨一倍多
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.